INTUITIVE SURGICAL INC

Intuitive Surgical announced a leadership transition effective July 1, 2026. Henry L. Charlton will move from his role as Chief Commercial and Marketing Officer to Senior Vice President of Global Business Operations. Taylor Patton, currently Global Senior Vice President, Endoluminal, will succeed Mr. Charlton as the new Chief Commercial and Marketing Officer and join the Executive Leadership team. The company highlighted Patton's extensive experience across its platforms and Charlton's significant contributions.

Intuitive announced the promotion of Taylor Patton to Chief Commercial and Marketing Officer, effective July 1, where he will join the Executive Leadership team. Patton, with nearly two decades at Intuitive, will leverage his experience across the company's platforms to scale commercial operations and enhance customer support globally. Henry Charlton, the outgoing Chief Commercial and Marketing Officer, will transition to the role of Senior Vice President of Global Business Operations, focusing on generating value for global healthcare systems and ensuring world-class customer support.

Intuitive Surgical announced significant innovations for its da Vinci 5 surgical system, including over 100 user experience improvements and enhanced Telepresence capabilities. The company also extended the use of five Force Feedback instruments from six to 15 uses, aiming to lower per-procedure costs and meet customer demand. These advancements, along with improved product reliability and enhanced instrument security, reflect Intuitive's commitment to improving patient care and surgeon experience.

Intuitive Surgical's Board increased the authorized amount for its common stock repurchase program to an aggregate of $5.0 billion. Additionally, stockholders approved the amendment and restatement of the 2010 Incentive Award Plan, which increases the shares reserved for issuance by 5,000,000 to 125,350,000 and extends its term to 2036. At the annual meeting, stockholders also elected ten directors, approved executive compensation on an advisory basis, and ratified PricewaterhouseCoopers LLP as the independent auditor.

Intuitive Surgical, Inc. filed its Form 10-Q for the quarter ended March 31, 2026. The company reported a decrease in cash and cash equivalents to $2,006.5 million from $3,368.0 million at the end of 2025. Total current assets also declined to $8,809.5 million from $9,779.5 million. Conversely, accounts receivable and inventory saw increases, indicating potential sales activity but also tied-up capital.

Intuitive Surgical reported strong first-quarter 2026 financial results, with revenue increasing 23% to $2.77 billion, driven by significant growth in procedure volumes and system placements. Worldwide procedures grew 17%, with da Vinci procedures up 16% and Ion procedures up 39%. The company also saw a substantial rise in GAAP net income and diluted EPS, alongside a $1.1 billion share repurchase program.

Intuitive Surgical announced strong first-quarter 2026 financial results, highlighted by significant growth in surgical procedures and system placements. Worldwide procedures, combining da Vinci and Ion, increased by approximately 17% year-over-year. The company placed 431 da Vinci surgical systems, a notable increase from 367 in the prior year's first quarter, indicating robust demand for its robotic-assisted surgery platforms.

Brian E. Miller, Ph.D., Chief Digital Officer of Intuitive Surgical, will transition to Head of Digital and AI Strategy, effective January 1, 2026. In his new role, Dr. Miller will no longer report directly to the CEO, indicating a shift in the organizational structure and potentially the strategic importance of the digital and AI functions within the company.

Intuitive Surgical reported preliminary unaudited Q4 2025 revenue of $2.87 billion, a 19% increase year-over-year. Total system placements increased by 8% to 532 units, driven by growth in the United States and Europe, while procedures grew 17% to 849,000. The company's recurring revenue stream remains strong at 81% of total revenue.

Intuitive Surgical reported strong Q4 2025 results, with revenue increasing by 19% year-over-year to $2.87 billion. The growth was driven by increased da Vinci and Ion procedure volumes, higher da Vinci system placements, and a larger installed base. The company also increased its contribution to the Intuitive Foundation.